PE20030720A1 - Ligandos de los receptores de los cannabinoides - Google Patents
Ligandos de los receptores de los cannabinoidesInfo
- Publication number
- PE20030720A1 PE20030720A1 PE2002001100A PE2002001100A PE20030720A1 PE 20030720 A1 PE20030720 A1 PE 20030720A1 PE 2002001100 A PE2002001100 A PE 2002001100A PE 2002001100 A PE2002001100 A PE 2002001100A PE 20030720 A1 PE20030720 A1 PE 20030720A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- covalent link
- haloalkyl
- cycloalkyl
- cannabinoid receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A LIGANDOS DE LOS RECEPTORES DE CANNABINOIDES DE FORMULA I DONDE L1 ES UN ENLACE COVALENTE, -CH2-, -C(O), -C(O)O-, SO2, -S-, ENTRE OTROS; L2 ES -CH2-, -C(H)(ALQUIL)-, -C(ALQUIL)2-, -C(O)-, -SO-, ENTRE OTROS; L3 ES UN ENLACE COVALENTE, -C(O)-, -S(O2)-; R1 ES H, HALOGENO, ALQUILO, HALOALQUILO, CICLOALQUILO, CICLOALQUILALQUILO, HETEROCICLILALQUILO, -CHR7-, ENTRE OTROS; CON LA CONDICION DE QUE CUANDO R1 ES HALO, L1 ES UN ENLACE COVALENTE, CUANDO R1 ES -NHR7, L1 ES UN ENLACE COVALENTE, -CH2-, -C(O)-, SO2, -SO-, ENTRE OTROS; R2 ES H, OH, HALO, -CF3, ALCOXI, ALQUILO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO; R3 Y R4 TOMADOS CONJUNTAMENTE FORMAN UN GRUPO CARBONILO ES DECIR C(=O); R5 ES H, ALQUILO; R6 ES H, ALQUILO, HALOALQUILO, CICLOALQUILO, NHR7, N(R7)2, ARILO, HETEROARILO, ENTRE OTROS; R7 ES H, ALQUILO, HALOALQUILO, CICLOALQUILO, HETEROCICLILALQUILO, ENTRE OTROS; A ES FENILO, NAFTILO, PIRIDILO, TIENILO, TIAZOLILO, INDOLILO, QUINOLILO, ISOQUINOLILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS PRESENTAN UNA ACTIVIDAD ANTIINFLAMATORIA E INMUNOMODULADORA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33291101P | 2001-11-14 | 2001-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030720A1 true PE20030720A1 (es) | 2003-08-29 |
Family
ID=23300394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002001100A PE20030720A1 (es) | 2001-11-14 | 2002-11-13 | Ligandos de los receptores de los cannabinoides |
Country Status (20)
Country | Link |
---|---|
US (2) | US7071213B2 (es) |
EP (1) | EP1444203A1 (es) |
JP (2) | JP2005509032A (es) |
KR (1) | KR20050044417A (es) |
CN (2) | CN100567266C (es) |
AR (1) | AR037352A1 (es) |
BR (1) | BR0214164A (es) |
CA (1) | CA2466440A1 (es) |
EC (1) | ECSP045104A (es) |
HU (1) | HUP0401924A3 (es) |
IL (1) | IL161439A0 (es) |
MX (1) | MXPA04004674A (es) |
NO (1) | NO20042435L (es) |
NZ (1) | NZ532291A (es) |
PE (1) | PE20030720A1 (es) |
PL (1) | PL369952A1 (es) |
RU (1) | RU2004117907A (es) |
TW (1) | TW200302088A (es) |
WO (1) | WO2003042174A1 (es) |
ZA (1) | ZA200403685B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
HUP0401924A3 (en) | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
CN1662496A (zh) | 2002-06-19 | 2005-08-31 | 先灵公司 | 大麻素受体激动剂 |
MXPA05005512A (es) | 2002-11-25 | 2005-07-25 | Schering Corp | Ligandos receptores canabinoides. |
BRPI0408332A (pt) | 2003-03-14 | 2006-03-21 | Ono Pharmaceutical Co | derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
BRPI0408682A (pt) | 2003-03-24 | 2006-03-28 | Actimis Pharmaceuticals Inc | derivado de benzenossulfonamida, medicamento, uso do derivado de benzenossulfonamida, e, processo para controlar uma doença ou distúrbio inflamatórios ou imuno-reguladores em humanos e animais |
US6916852B2 (en) * | 2003-05-12 | 2005-07-12 | University Of Tennessee Research Foundation | Method for regulation of microvascular tone |
JP2007501279A (ja) * | 2003-05-20 | 2007-01-25 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション | カンナビノイド誘導体、その製造方法、および使用 |
AU2004276337B2 (en) * | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
PL1701940T3 (pl) * | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
JP2007523202A (ja) * | 2004-02-24 | 2007-08-16 | ビオアクソン・テラプティーク・インコーポレーテッド | 4置換ピペリジン誘導体 |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
ATE444066T1 (de) | 2004-06-22 | 2009-10-15 | Schering Corp | Liganden für den cannabinoidrezeptoren |
AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
CN101775013A (zh) | 2004-09-13 | 2010-07-14 | 小野药品工业株式会社 | 含氮杂环衍生物及含有其作为活性成分的药物 |
US7776886B2 (en) * | 2004-09-30 | 2010-08-17 | Merck Sharp & Dohme Corp. | Cyclopropyl piperidine glycine transporter inhibitors |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US7629473B2 (en) * | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
US20100222387A1 (en) * | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
EP1901746B1 (en) * | 2005-06-29 | 2013-02-20 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine t-type calcium channel antagonists |
WO2007053400A2 (en) * | 2005-10-28 | 2007-05-10 | Merck & Co., Inc. | Piperidine glycine transporter inhibitors |
GB0523609D0 (en) * | 2005-11-19 | 2005-12-28 | Vernalis R&D Ltd | Piperazine derivatives |
JP2009525954A (ja) * | 2006-01-13 | 2009-07-16 | シェーリング コーポレイション | Cb1モジュレーターとしてのジアリールピペリジン |
WO2007105637A1 (ja) * | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
AU2007234843B2 (en) * | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
AU2006348180A1 (en) * | 2006-09-13 | 2008-03-20 | Warner Chilcott Company, Llc | Methods of treatment for ulcerative colitis |
FR2907784B1 (fr) * | 2006-10-27 | 2009-02-13 | Sod Conseils Rech Applic | Derives phenyliques et leur utilisation comme medicament |
EP2120938A4 (en) * | 2006-12-20 | 2010-12-08 | Merck Sharp & Dohme | IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES |
US9023831B2 (en) * | 2007-04-24 | 2015-05-05 | Novelmed Therapeutics, Inc. | Methods and compositions of inhibiting complement and cellular activation with Dextran Sulfate |
WO2010077624A1 (en) | 2008-12-09 | 2010-07-08 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
EP2375899B1 (en) * | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
EP2749554B1 (en) * | 2009-04-22 | 2017-12-20 | SMA Therapeutics, Inc. | 2,5-disubstituted arylsulfonamide CCR3 antagonists |
US8258158B2 (en) | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
GB201103419D0 (es) * | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES |
CN114867720A (zh) | 2020-01-16 | 2022-08-05 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3702324A (en) * | 1970-06-24 | 1972-11-07 | Stanford Research Inst | 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines |
US4486965A (en) * | 1982-05-14 | 1984-12-11 | Nike, Inc. | Footwear with overlapping closure strap means |
US4466965A (en) * | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
US4567184A (en) * | 1982-12-01 | 1986-01-28 | Usv Pharmaceutical Corporation | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies |
NO174506B (no) | 1984-10-30 | 1994-02-07 | Usv Pharma Corp | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
US5332820A (en) * | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
JPH0672979A (ja) | 1992-06-08 | 1994-03-15 | Hiroyoshi Hidaka | アミノベンジル誘導体 |
US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
JP3254745B2 (ja) | 1992-08-27 | 2002-02-12 | 住友化学工業株式会社 | ジオール化合物およびその製造法 |
US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
TW406075B (en) * | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
EA000304B1 (ru) | 1995-02-02 | 1999-04-29 | Смитклайн Бичам Плс | Производные индола как антагонисты рецептора 5-ht |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
JPH11510485A (ja) | 1995-07-21 | 1999-09-14 | ニィコメド・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 酵素のシクロオキシゲナーゼiiの阻害剤としてのベンゼンスルホンアミドの誘導体 |
DE19533644A1 (de) | 1995-09-12 | 1997-03-13 | Nycomed Arzneimittel Gmbh | Neue Benzolsulfonamide |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
KR19990082330A (ko) | 1996-02-06 | 1999-11-25 | 미즈노 마사루 | 신규 화합물 및 이의 의약 용도 |
CA2264037A1 (en) | 1996-09-13 | 1998-03-19 | Merck & Co., Inc. | Thrombin inhibitors |
WO1998031227A1 (en) | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
KR100630530B1 (ko) | 1997-10-24 | 2006-09-29 | 닛산 가가쿠 고교 가부시키 가이샤 | 술파모일 화합물 및 농원예용 살균제 |
WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
PL343249A1 (en) | 1998-03-26 | 2001-07-30 | Shionogi & Co | Indole derivatives with antiviral activity |
CN1310621A (zh) | 1998-07-28 | 2001-08-29 | 史密丝克莱恩比彻姆公司 | 取代的n-酰苯胺化合物和方法 |
MXPA02004985A (es) | 1999-11-26 | 2003-10-14 | Shionogi & Co | Antagonistas del neuropeptido y, y5. |
AU2092601A (en) | 1999-12-15 | 2001-06-25 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
US20020052343A1 (en) | 1999-12-15 | 2002-05-02 | Allen Darin Arthur | Salicylamides as serine protease inhibitors |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001070754A1 (en) | 2000-03-22 | 2001-09-27 | Merck Frosst Canada & Co. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
US7132567B2 (en) | 2000-04-03 | 2006-11-07 | Cerno Biosciences, Llc | Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins |
MXPA02010693A (es) | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
AU2001258771A1 (en) | 2000-05-19 | 2001-11-26 | Takeda Chemical Industries Ltd. | -secretase inhibitors |
US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
HUP0401924A3 (en) | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
-
2002
- 2002-11-12 HU HU0401924A patent/HUP0401924A3/hu unknown
- 2002-11-12 CN CNB028226755A patent/CN100567266C/zh not_active Expired - Fee Related
- 2002-11-12 NZ NZ532291A patent/NZ532291A/en unknown
- 2002-11-12 WO PCT/US2002/036185 patent/WO2003042174A1/en active IP Right Grant
- 2002-11-12 BR BR0214164-7A patent/BR0214164A/pt not_active IP Right Cessation
- 2002-11-12 US US10/292,778 patent/US7071213B2/en not_active Expired - Fee Related
- 2002-11-12 IL IL16143902A patent/IL161439A0/xx unknown
- 2002-11-12 AR ARP020104334A patent/AR037352A1/es unknown
- 2002-11-12 CN CN200910207711A patent/CN101684091A/zh active Pending
- 2002-11-12 CA CA002466440A patent/CA2466440A1/en not_active Abandoned
- 2002-11-12 TW TW091133142A patent/TW200302088A/zh unknown
- 2002-11-12 RU RU2004117907/04A patent/RU2004117907A/ru not_active Application Discontinuation
- 2002-11-12 KR KR1020047007188A patent/KR20050044417A/ko not_active Application Discontinuation
- 2002-11-12 MX MXPA04004674A patent/MXPA04004674A/es unknown
- 2002-11-12 EP EP02784433A patent/EP1444203A1/en not_active Withdrawn
- 2002-11-12 JP JP2003544011A patent/JP2005509032A/ja active Pending
- 2002-11-12 PL PL02369952A patent/PL369952A1/xx not_active Application Discontinuation
- 2002-11-13 PE PE2002001100A patent/PE20030720A1/es not_active Application Discontinuation
-
2004
- 2004-05-12 EC EC2004005104A patent/ECSP045104A/es unknown
- 2004-05-13 ZA ZA200403685A patent/ZA200403685B/en unknown
- 2004-06-11 NO NO20042435A patent/NO20042435L/no unknown
-
2005
- 2005-08-05 US US11/197,979 patent/US7645774B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 JP JP2009245983A patent/JP2010018635A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ZA200403685B (en) | 2005-05-23 |
IL161439A0 (en) | 2004-09-27 |
EP1444203A1 (en) | 2004-08-11 |
PL369952A1 (en) | 2005-05-02 |
WO2003042174A1 (en) | 2003-05-22 |
AR037352A1 (es) | 2004-11-03 |
BR0214164A (pt) | 2004-09-28 |
CN100567266C (zh) | 2009-12-09 |
US7645774B2 (en) | 2010-01-12 |
US7071213B2 (en) | 2006-07-04 |
US20040010013A1 (en) | 2004-01-15 |
KR20050044417A (ko) | 2005-05-12 |
US20050282861A1 (en) | 2005-12-22 |
JP2005509032A (ja) | 2005-04-07 |
CN1585749A (zh) | 2005-02-23 |
NO20042435L (no) | 2004-06-11 |
HUP0401924A3 (en) | 2009-07-28 |
JP2010018635A (ja) | 2010-01-28 |
CA2466440A1 (en) | 2003-05-22 |
ECSP045104A (es) | 2004-06-28 |
TW200302088A (en) | 2003-08-01 |
MXPA04004674A (es) | 2004-08-12 |
NZ532291A (en) | 2005-11-25 |
HUP0401924A2 (hu) | 2005-01-28 |
CN101684091A (zh) | 2010-03-31 |
RU2004117907A (ru) | 2006-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030720A1 (es) | Ligandos de los receptores de los cannabinoides | |
DZ1785A1 (fr) | Nouveaux composés. | |
DK1135166T3 (da) | Hapten-bærer-konjugat til behandling og forebyggelse af nicotinafhængighed | |
ES547275A0 (es) | Un procedimiento para preparar derivados de dihidropiridina | |
SE8704298D0 (sv) | Compounds for use in therapy | |
ATE86491T1 (de) | Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen. | |
DE3786843D1 (de) | Chinolincarbonsaeurederivate. | |
DE60134899D1 (de) | Herstellung von Risperidon | |
LU86077A1 (fr) | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques | |
CO4700452A1 (es) | Derivados de indol | |
DE3764724D1 (de) | 2-phenylbenzoxepin-derivat. | |
DK545889A (da) | Anti-human-immundefektvirus-praeparat | |
DK132188A (da) | Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika | |
DK0599240T3 (da) | Indol-7-carboxamidderivater som analgetika | |
ES2070002T3 (es) | Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona. | |
DK707988D0 (da) | Fremgangsmaade til at haemme virus | |
KR920007995A (ko) | 벤즈아미드 유도체 | |
DE69804169T2 (de) | Oral anzuwendende flüssige Arzneilösung | |
SE9601708D0 (sv) | Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
DE69015324T2 (de) | Herstellung von gegebenenfalls substituierten Chinolincopolymeren. | |
ES2053530T3 (es) | Compuestos macrolidos. | |
CO5300520A1 (es) | Nuevos compuestos de sulfonamida y usos de los mismos | |
ES517040A0 (es) | Procedimiento para la preparacion de una imidazolcarboxamida. | |
FR2601246B1 (fr) | Nouvelles compositions anti-tussives a base de dextromethorphane et leur procede d'obtention. | |
DE68920168T2 (de) | 2-Substituierte Carbonylimidazo[4,5-c]chinoline. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |